<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The <z:chebi fb="40" ids="18243">dopamine</z:chebi> (<z:mp ids='MP_0000273'>DA</z:mp>) uptake sites in the caudate nucleus were studied in patients with vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> (VAD) and in a control group using the presynaptic <z:mp ids='MP_0000273'>DA</z:mp> uptake site marker [3H][2beta-carbomethoxy-3beta-(4-fluorophenyl) <z:chebi fb="0" ids="35615">tropane</z:chebi>] as radioligand </plain></SENT>
<SENT sid="1" pm="."><plain>There was a significant decrease in the number of <z:mp ids='MP_0000273'>DA</z:mp> uptake sites in the VAD group, while the binding affinity was unchanged </plain></SENT>
<SENT sid="2" pm="."><plain>The present results indicate that in the patients investigated, the cerebrovascular disease process involves dopaminergic neuron terminals in the caudate nucleus </plain></SENT>
<SENT sid="3" pm="."><plain>Our findings are discussed in relation to the reductions in number of <z:mp ids='MP_0000273'>DA</z:mp> uptake sites that have previously been revealed in Alzheimer's and <z:e sem="disease" ids="C0030567" disease_type="Disease or Syndrome" abbrv="PD">Parkinson's diseases</z:e> </plain></SENT>
</text></document>